GGAL vs HUT

The deterministic health profile is critically weak, highlighted by a Piotroski F-Score of 2/9 and a massive valuation gap where the current price ($47.93) trades at a significant premium to the Graham Number ($8.34) and Intrinsic Value ($6.23). While long-term price performance has been exceptional, current fundamentals show severe deterioration, including a negative YoY revenue growth of 10% and a catastrophic earnings surprise trend (-149.13% over the last 4 quarters). The dividend is unsustainable with a payout ratio of 123.58%, suggesting capital erosion. Despite bullish analyst targets, the hard data indicates a high-risk, overvalued asset.

HUT exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the stock has seen massive 1-year price appreciation and maintains a 'strong_buy' analyst consensus, there is a dangerous disconnect between market sentiment and operational reality. The company suffers from an unsustainable operating margin of -497.74% and a precarious liquidity position with a Quick Ratio of 0.20. Valuation is extreme, with a Price/Sales ratio of 31.17, suggesting the current price is driven by speculation rather than intrinsic value.